Disclosed is the use of a pharmaceutical composition that contains 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide (acumapimod) or a pharmaceutically acceptable salt, hydrate or solvate thereof in the manufacture of a medicament for the treatment of acute exacerbations of chronic obstructive pulmonary disease, wherein the pharmaceutical composition is adapted for oral administration, preferably in the form of a tablet. Acumapimod is also known as BCT-197, BCT197A2201 having CAS#: 836683-15-9).
